Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism

被引:54
作者
Park, DS
Razani, B
Lasorella, A
Schreiber-Agus, N
Pestell, RG
Iavarone, A
Lisanti, MP
机构
[1] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA
[4] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA
关键词
D O I
10.1021/bi002787b
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The c-Myc oncoprotein contributes to oncogenesis by activating and repressing a repertoire of genes involved in cellular proliferation, metabolism, and apoptosis. Increasing evidence suggests that the repressor function of c-Myc is critical for transformation. Therefore, identifying and characterizing Myc-repressed genes is imperative to understanding the mechanisms of Myc-induced tumorigenesis, Here, we employ NIH 3T3 cell lines harboring c-Myc-ER or N-Myc-ER to dissect the relationship between Myc activation and caveolin-l expression. In this well-established inducible system, treatment with estrogen like molecules, such as tamoxifen, leads to activation of Myc, but in a tightly controlled fashion. Using this approach, we show that Myc activation induces the repression of caveolin-l expression at the transcriptional level. We also provide two independent lines of evidence suggesting that caveolin-l is a direct target of Myc: (i) the effect of Myc activation on caveolin-l expression is independent of new protein synthesis, as revealed through the use of cycloheximide; and (ii) Myc-mediated repression of the caveolin-l promoter is dependent on an intact INR sequence, Moreover, we show that expression of caveolin-l, via an adenoviral vector approach, can suppress cell transformation that is mediated by Myc activation. In support of these observations, treatment with an adenoviral vector harboring anti-sense caveolin-l specifically potentiates transformation induced by Myc activation. Taken together, our results indicate that caveolin-l is a direct target of Myc repression, and they also provide evidence for an additional mechanism by which Myc repression can elicit a malignant phenotype.
引用
收藏
页码:3354 / 3362
页数:9
相关论文
共 56 条
[1]   SEQUENCE-SPECIFIC TRANSCRIPTIONAL ACTIVATION BY MYC AND REPRESSION BY MAX [J].
AMIN, C ;
WAGNER, AJ ;
HAY, N .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :383-390
[2]   Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression [J].
Bagnoli, M ;
Tomassetti, A ;
Figini, M ;
Flati, S ;
Dolo, V ;
Canevari, S ;
Miotti, S .
ONCOGENE, 2000, 19 (41) :4754-4763
[3]   CHARACTERIZATION OF THE HUMAN N-CAM PROMOTER [J].
BARTON, CH ;
MANN, DA ;
WALSH, FS .
BIOCHEMICAL JOURNAL, 1990, 268 (01) :161-168
[4]  
Bender FC, 2000, CANCER RES, V60, P5870
[5]   CCAAT ENHANCER BINDING-PROTEIN GENE PROMOTER - BINDING OF NUCLEAR FACTORS DURING DIFFERENTIATION OF 3T3-L1 PREADIPOCYTES [J].
CHRISTY, RJ ;
KAESTNER, KH ;
GEIMAN, DE ;
LANE, MD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (06) :2593-2597
[6]   Myc-mediated transformation: the repression connection [J].
Claassen, GF ;
Hann, SR .
ONCOGENE, 1999, 18 (19) :2925-2933
[7]   DESCRIPTION OF THE LEUKOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 (LFA-1 OR CD11A) PROMOTER [J].
CORNWELL, RD ;
GOLLAHON, KA ;
HICKSTEIN, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (09) :4221-4225
[8]   Interaction of a receptor tyrosine kinase, EGF-R, with caveolins - Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities [J].
Couet, J ;
Sargiacomo, M ;
Lisanti, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (48) :30429-30438
[9]   Function of the c-Myc oncogenic transcription factor [J].
Dang, CV ;
Resar, LMS ;
Emison, E ;
Kim, S ;
Li, Q ;
Prescott, JE ;
Wonsey, D ;
Zeller, K .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :63-77
[10]  
DEPINHO RA, 1991, ADV CANCER RES, V57, P1